Clinical trials
Immunity clinical trials
Below are recruiting immunity clinical trials, each written for real people, not researchers. We’re tracking 973 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07034339Recruiting
Immune map for pancreatic cancer evolution
This study builds an immune map of how pancreatic cancer changes over time. It may help doctors better understand the disease and find new treatment strategies.
Hangzhou, ZhejiangAges 18–80 - NCT07034326RecruitingPhase 2/Phase 3
Acupuncture plus immunotherapy after lung cancer surgery
This trial explores whether adding electroacupuncture (a gentle needle treatment with mild electric pulses) to standard immunotherapy after lung cancer surgery can help prevent the cancer from coming back. It is designed for people with early-stage non-small cell lung cancer who have already had chemotherapy.
TianjinAges 18–80 - NCT05867004Recruiting
Block TNF to boost immune response in melanoma
This study looks at using a drug that blocks TNF to help the immune system “wake up” better when using cancer immunotherapy for melanoma. You may be eligible only if you are already enrolled in two specific related trials.
ToulouseAges 18 years+ - NCT07033663Recruiting
Monoclonal antibody exposure during pregnancy and baby's immune system
This study looks at how monoclonal antibody treatments given during pregnancy affect a baby's immune system development. It compares babies whose mothers received these treatments throughout pregnancy, only in early pregnancy, or not at all.
Esplugues de Llobregat, BarcelonaAges Any age - NCT07017725RecruitingPhase 1/Phase 2
Testing a new drug for chronic low platelets
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
Tangshan, HebeiAges 18–65 - NCT07007962RecruitingPhase 3
Oral pill for immune thrombocytopenia after first treatment fails
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
Clovis, CaliforniaAges 18 years+ - NCT06989541Recruiting
Immunoglobulin for low antibodies after CAR T-cell therapy
This trial tests whether giving immunoglobulin (a treatment that boosts your antibodies) can help people who developed very low antibody levels after CAR T-cell therapy for cancer. It may help prevent infections and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06973356Recruiting
CAR-T therapy for severe, hard-to-treat ITP
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
Changsha, HunanAges 18 years+ - NCT06977594Recruiting
Preventing allergic reactions during chemo for gynecologic cancer
This study tests a proactive approach to reduce allergic reactions to common chemotherapy drugs (paclitaxel and carboplatin) used for gynecologic cancers. It aims to make treatment safer and more comfortable for patients.
SeoulAges 19 years+ - NCT06950697Recruiting
Blood clot risk prediction for lung cancer patients on immunotherapy
This study builds a tool to predict blood clot risk in lung cancer patients receiving immune checkpoint inhibitors. Researchers will use your data to develop a more personalized risk assessment, which may help prevent dangerous clots during treatment.
Zhengzhou, HenanAges 18 years+ - NCT06948318RecruitingPhase 3
Follow-up study of mezagitamab for chronic ITP
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
Hot Springs, ArkansasAges 18 years+ - NCT06930976Recruiting
Tracing sugar use in immune cells
This study uses a special sugar (glucose) to see how your immune cells use energy. You drink a labeled sugar, then give blood samples so researchers can track it.
Nashville, TennesseeAges 18 years+ - NCT06929299RecruitingPhase 1/Phase 2
Testing STSA-1301 for immune thrombocytopenia (ITP)
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
Bengbu, AnhuiAges 18–75 - NCT06789601RecruitingPhase 1/Phase 2
Better tracking of immunotherapy side effects study
This trial aims to improve how doctors spot and track side effects from immunotherapy. If you are on or have had immunotherapy, your experience can help build a better system for monitoring these treatments.
Boston, MassachusettsAges Any age - NCT06910657RecruitingPhase 1
IDOV-Immune vaccine for advanced solid tumors
This trial tests an experimental virus-based treatment for people with advanced solid tumors that have stopped responding to standard therapies. The treatment is designed to infect and destroy cancer cells while boosting the immune system.
St Louis, MissouriAges 18 years+ - NCT06718127Recruiting
Study of immune response to yellow fever vaccine
This study looks at how your body's immune system responds to the yellow fever vaccine. It may help researchers understand how well the vaccine protects people.
ParisAges 18–65 - NCT06880081RecruitingPhase 1
A study of PN20 for adults with immune thrombocytopenia
This trial tests a new drug called PN20 for adults with a long-term low platelet condition called immune thrombocytopenia (ITP). It aims to see if the drug can safely raise platelet counts for people who have not gotten better with other treatments.
Guiyang, GuizhouAges 18–65 - NCT06864481Recruiting
Study of liver inflammation from immunotherapy drugs
This study follows people who develop liver inflammation (hepatitis) after starting immunotherapy for cancer. It helps doctors understand how often this happens and how to manage it.
MontpellierAges 18 years+ - NCT06853223RecruitingPhase 2
Immune drug to prevent lung transplant failure
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
San Francisco, CaliforniaAges 18 years+ - NCT06848309Recruiting
Immune response study for influenza or COVID-19
This study looks at how your immune system fights off flu or COVID-19. If you have a current or recent infection, or if you've been vaccinated in the past year, you may be able to join.
St Louis, MissouriAges 18–60 - NCT06838962RecruitingPhase 2
Study of anti-CD38 antibody for children with chronic ITP
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 6–18 - NCT06841705RecruitingPhase 2
Early vedolizumab as first treatment for colitis from immunotherapy
This trial tests if giving vedolizumab early can help control severe diarrhea and colon inflammation caused by immunotherapy (a type of cancer treatment). It may offer a new option for people who develop these side effects.
Boston, MassachusettsAges 18 years+ - NCT06831058RecruitingPhase 2
Efgartigimod for preventing iTTP relapses
This study tests a drug called efgartigimod to see if it can prevent relapses in people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are currently in remission. It may help by reducing the immune activity that causes the condition.
Minneapolis, MinnesotaAges 18 years+ - NCT06832514RecruitingPhase 4
Gender and immune response to meningitis B vaccine
This study tests how well the meningitis B vaccine works in transgender and cisgender people. It aims to understand if sex and gender affect immune responses.
GhentAges 18–50
Hear when a new Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunity?
- Yes. Clin2 currently lists 973 recruiting immunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.